A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

Vaccine

Volumn 25, Issue 28, 2007, Pages 5189-5198

  Youn, Hyun Jun ^a   Ko, Sung Youl ^a   Lee, Kyoo A ^a   Ko, Hyun Jeong ^a   Lee, Yoon Sook ^a   Fujihashi, Kohtaro ^b   Boyaka, Prosper N ^c   Kim, Sang Hee ^d   Horimoto, Taisuke ^e   Kweon, Mi Na ^f   Kang, Chang Yuil ^a  

^a Tumor Microenvironment Global Core Research Center   (South Korea)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Seoul National University   (South Korea)

^e UNIVERSITY OF TOKYO   (Japan)

^f International Vaccine Institute   (South Korea)

Author keywords

Inactivated influenza virus; Nasal vaccination; Natural killer T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED INFLUENZA VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; IMMUNIZATION; INFLUENZA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; CENTRAL NERVOUS SYSTEM; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALACTOSYLCERAMIDES; IMMUNITY, CELLULAR; IMMUNIZATION; INFLUENZA VACCINES; KAPLAN-MEIERS ESTIMATE; KILLER CELLS, NATURAL; LYMPHOCYTES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TH2 CELLS; TIME FACTORS; VACCINES, INACTIVATED;

EID: 34250219958     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.081     Document Type: Article

References (38)

1. Simonsen L., Fukuda K., Schonberger L.B., and Cox N.J. The impact of influenza epidemics on hospitalizations. J Infect Dis 181 3 (2000) 831-837
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 11 (2004) 1333-1340
3. Webster R.G., Sharp G.B., and Claas E.C. Interspecies transmission of influenza viruses. Am J Respir Crit Care Med 152 4 Pt 2 (1995) S25-S30
4. 2 reassortant influenza A viruses in North American pigs. Vet Microbiol 74 1/2 (2000) 47-58
5. Brokstad K.A., Eriksson J.C., Cox R.J., Tynning T., Olofsson J., Jonsson R., et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 185 7 (2002) 878-884
6. Provinciali M., Di Stefano G., Muzzioli M., Scarpazza P., Colombo D., Migliorino M., et al. Impaired antibody response to influenza vaccine in institutionalized elderly. Ann N Y Acad Sci 717 (1994) 307-314
7. Belshe R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Res 103 1/2 (2004) 177-185
8. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282 2 (1999) 137-144
9. Akbari O., DeKruyff R.H., and Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2 8 (2001) 725-731
10. Marinaro M., Di Tommaso A., Uzzau S., Fasano A., and De Magistris M.T. Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect Immun 67 3 (1999) 1287-1291
11. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 5343 (1997) 1626-1629
12. Burdin N., and Kronenberg M. CD1-mediated immune responses to glycolipids. Curr Opin Immunol 11 3 (1999) 326-331
13. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21 (2003) 483-513
14. Wilson M.T., Singh A.K., and Van Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med 8 5 (2002) 225-231
15. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 58 6 (1998) 1202-1207
16. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95 10 (1998) 5690-5693
17. Gonzalez-Aseguinolaza G., de Oliveira C., Tomaska M., Hong S., Bruna-Romero O., Nakayama T., et al. alpha-Galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 97 15 (2000) 8461-8466
18. Kakimi K., Guidotti L.G., Koezuka Y., and Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192 7 (2000) 921-930
19. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 2 (2003) 267-279
20. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114 12 (2004) 1800-1811
21. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., and Kang C.Y. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175 5 (2005) 3309-3317
22. Kim S., Song S., Lee T., Jung S., and Kim D. Practical synthesis of KRN7000 from phytosphingosine. Synthesis 6 (2004) 847-850
23. Tobita K. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol (Berl) 162 1 (1975) 23-27
24. Tobita K., Sugiura A., Enomote C., and Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol (Berl) 162 1 (1975) 9-14
25. Watanabe I., Hagiwara Y., Kadowaki S.E., Yoshikawa T., Komase K., Aizawa C., et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20 29/30 (2002) 3443-3455
26. Uren T.K., Johansen F.E., Wijburg O.L., Koentgen F., Brandtzaeg P., and Strugnell R.A. Role of the polymeric Ig receptor in mucosal B cell homeostasis. J Immunol 170 5 (2003) 2531-2539
27. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176 3 (2006) 1776-1783
28. Stober D., Jomantaite I., Schirmbeck R., and Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 170 5 (2003) 2540-2548
29. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73 10 (2005) 6892-6902
30. Bracci L., Canini I., Puzelli S., Sestili P., Venditti M., Spada M., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 23 (2005) 2994-3004
31. Hasegawa H., Ichinohe T., Strong P., Watanabe I., Ito S., Tamura S., et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol 75 1 (2005) 130-136
32. Singh N., Hong S., Scherer D.C., Serizawa I., Burdin N., Kronenberg M., et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 163 5 (1999) 2373-2377
33. Burdin N., Brossay L., and Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 29 6 (1999) 2014-2025
34. Cui J., Watanabe N., Kawano T., Yamashita M., Kamata T., Shimizu C., et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. J Exp Med 190 6 (1999) 783-792
35. Szewczuk M.R., Campbell R.J., and Jung L.K. Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. J Immunol 126 6 (1981) 2200-2204
36. Almeida A.J., and Alpar H.O. Nasal delivery of vaccines. J Drug Target 3 6 (1996) 455-467
37. Okuda K., Ihata A., Watabe S., Okada E., Yamakawa T., Hamajima K., et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19 27 (2001) 3681-3691
38. Lamb J.R., Eckels D.D., Phelan M., Lake P., and Woody J.N. Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J Immunol 128 3 (1982) 1428-1432